Otsuka Drug Patent Portfolio
Otsuka owns 8 orange book drugs protected by 84 US patents with Raxar having the least patent protection, holding only 1 patent. And Abilify Mycite Kit with maximum patent protection, holding 38 patents. Given below is the list of Otsuka's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963971 | Combination decitabine and cedazuridine solid oral dosage forms | 24 Feb, 2041 | Active |
| US10097388 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | 19 Sep, 2034 | Active |
| US9270503 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | 19 Sep, 2034 | Active |
| US9787511 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping | 19 Sep, 2034 | Active |
| US9268909 | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device | 15 Oct, 2033 | Active |
| US9577864 | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance | 03 Oct, 2033 | Active |
| US10517951 | Injectable preparation | 23 Apr, 2033 | Active |
| US11097007 | Injectable preparation | 23 Apr, 2033 | Active |
| US11638757 | Injectable preparation | 23 Apr, 2033 | Active |
| US12016927 | Injectable preparation | 23 Apr, 2033 | Active |
| US10307419 | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof | 12 Apr, 2033 | Active |
| US10307419 | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof | 12 Oct, 2032 | Active |
| US10517507 | Communication system with enhanced partial power source and method of manufacturing same | 13 Jun, 2032 | Active |
| US9320455 | Highly reliable ingestible event markers and methods for using the same | 15 Dec, 2031 | Active |
| US11229378 | Communication system with enhanced partial power source and method of manufacturing same | 11 Jul, 2031 | Active |
| US8547248 | Implantable zero-wire communications system | 18 Dec, 2030 | Active |
| US8258962 | Multi-mode communication ingestible event markers and systems, and methods of using the same | 25 Nov, 2030 | Active |
| US8961412 | In-body device with virtual dipole signal amplification | 17 Nov, 2030 | Active |
| US9941931 | System for supply chain management | 04 Nov, 2030 | Active |
| US11464423 | In-body power source having high surface area electrode | 15 Sep, 2030 | Active |
| US8268800 | Certain compounds, compositions and methods | 22 Aug, 2030 | Active |
| US8114021 | Body-associated receiver and method | 21 Jun, 2030 | Active |
| US8545402 | Highly reliable ingestible event markers and methods for using the same | 27 Apr, 2030 | Active |
| US10905694 | Pharmaceutical solid preparation comprising benzazepines and production method thereof | 07 Apr, 2030 | Active |
| US8847766 | Pharma-informatics system | 29 Mar, 2030 | Active |
| US9149577 | Body-associated receiver and method | 15 Dec, 2029 | Active |
| US8718193 | Active signal processing personal health signal receivers | 05 Dec, 2029 | Active |
| US9433371 | In-body device with virtual dipole signal amplification | 15 Sep, 2029 | Active |
| US8945005 | Controlled activation ingestible identifier | 19 Aug, 2029 | Active |
| US10441194 | Ingestible event marker systems | 26 Jul, 2029 | Active |
| US8956288 | In-body power source having high surface area electrode | 06 Jul, 2029 | Active |
| USRE48059 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 23 Jun, 2029 | Active |
| US8674825 | Pharma-informatics system | 09 Apr, 2029 | Active |
| US9060708 | Multi-mode communication ingestible event markers and systems, and methods of using the same | 05 Mar, 2029 | Active |
| US9258035 | Multi-mode communication ingestible event markers and systems, and methods of using the same | 05 Mar, 2029 | Active |
| USRE48059 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 23 Dec, 2028 | Active |
| US9119554 | Pharma-informatics system | 16 Dec, 2028 | Active |
| US8618075 | Certain compounds, compositions and methods | 16 Oct, 2028 | Active |
| US9567363 | Certain compounds, compositions and methods | 16 Oct, 2028 | Active |
| US9444503 | Active signal processing personal health signal receivers | 19 Nov, 2027 | Active |
| US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | 02 Mar, 2027 | Active |
| US7888362 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Oct, 2026 | Active |
| US8349840 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Oct, 2026 | Active |
| US8618109 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Oct, 2026 | Active |
| US9839637 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Oct, 2026 | Active |
| US7978064 | Communication system with partial power source | 14 Sep, 2026 | Active |
| US8501730 | Process for preparing benzazepine compounds or salts thereof | 01 Sep, 2026 | Active |
| US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders | 28 Jul, 2026 | Active |
| US11476952 | Pharma-informatics system | 28 Apr, 2026 | Active |
| US7888362 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Apr, 2026 | Active |
| US8349840 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Apr, 2026 | Active |
| US8618109 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Apr, 2026 | Active |
| US9839637 | Piperazine-substituted benzothiophenes for treatment of mental disorders | 12 Apr, 2026 | Active |
| US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 29 Jun, 2025 | Active |
| US8338427 | Methods for administering aripiprazole | 15 Mar, 2025 | Active |
| US7115587 | Aripiprazole complex formulation and method | 21 Jan, 2025 | Active |
| US7550445 | Aripiprazole complex formulation and method | 21 Jan, 2025 | Active |
| US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 16 Dec, 2024 | Active |
| US7115587 | Aripiprazole complex formulation and method | 21 Jul, 2024 | Expired |
| US7550445 | Aripiprazole complex formulation and method | 21 Jul, 2024 | Expired |
| US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 16 Jun, 2024 | Expired |
| US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | 25 Dec, 2023 | Expired |
| US8338428 | Methods for administering aripiprazole | 06 Aug, 2023 | Expired |
| US8759351 | Methods for administering aripiprazole | 06 Aug, 2023 | Expired |
| US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 25 Mar, 2023 | Expired |
| US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 25 Mar, 2023 | Expired |
| US6977257 | Aripiprazole oral solution | 24 Oct, 2022 | Expired |
| US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 25 Sep, 2022 | Expired |
| US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 25 Sep, 2022 | Expired |
| US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof | 25 Sep, 2022 | Expired |
| US8642600 | Method of treating autism | 28 Jul, 2022 | Expired |
| US6977257 | Aripiprazole oral solution | 24 Apr, 2022 | Expired |
| US7053092 | 5-HT1a receptor subtype agonist | 28 Jan, 2022 | Expired |
| US8642600 | Method of treating autism | 28 Jan, 2022 | Expired |
| US9089567 | Method of treating cognitive impairments and schizophrenias | 28 Jan, 2022 | Expired |
| US8518421 | Flashmelt oral dosage formulation | 24 Jul, 2021 | Expired |
| US8518421 | Flashmelt oral dosage formulation | 24 Jan, 2021 | Expired |
| US9358207 | Flashmelt oral dosage formulation | 12 Apr, 2020 | Expired |
| US5972882 | Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists | 14 Dec, 2018 | Expired |
| US5753677 | Benzoheterocyclic compounds | 19 May, 2015 | Expired |
| US5006528 | Carbostyril derivatives | 20 Apr, 2015 | Expired |
| US5006528 | Carbostyril derivatives | 20 Oct, 2014 | Expired |
| US5563138 | Benzoheterocyclic compounds | 08 Oct, 2013 | Expired |
| US5258510 | Benzoheterocyclic compounds | 02 Nov, 2012 | Expired |
Latest Legal Activities on Otsuka's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Otsuka.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Jul, 2024 | US10905694 |
|
Expire Patent
Critical
| 15 Jul, 2024 | US9359302 |
|
Expire Patent
Critical
| 15 Jul, 2024 | US9359302 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 26 Jun, 2024 | US8349840 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jun, 2024 | US8338428 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Jun, 2024 | US8338427 |
|
Email Notification
Critical
| 21 May, 2024 | US9149577 |
| Recordation of Patent eCertificate of Correction | 21 May, 2024 | US9149577 |
| Mail Patent eCofC Notification | 21 May, 2024 | US9149577 |
| Patent eCofC Notification | 21 May, 2024 | US9149577 |
| Post Issue Communication - Certificate of Correction | 01 May, 2024 | US9149577 |
| Mail Certificate of Correction Memo | 30 Apr, 2024 | US9149577 |
| Certificate of Correction Memo | 29 Apr, 2024 | US9149577 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 24 Apr, 2024 | US9149577 |
|
Email Notification
Critical
| 24 Apr, 2024 | US9149577 |
Otsuka's Drug Patent Litigations
Otsuka's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 17, 2016, against patent number US9125939. The petitioner Alkermes Pharma Ireland Limited, challenged the validity of this patent, with Otsuka Pharmaceutical Co., Ltd. as the respondent. Click below to track the latest information on how companies are challenging Otsuka's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US9125939 | November, 2016 |
Terminated-Denied
(04 May, 2017)
| Otsuka Pharmaceutical Co., Ltd. | Alkermes Pharma Ireland Limited |
Otsuka Drug Patents' Oppositions Filed in EPO
Otsuka drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 04, 2007, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP02782507A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP12840025A | Aug, 2020 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP12840025A | Aug, 2020 | Maiwald Patent- und Rechtsanwaltsgesellschaft mbH | Granted and Under Opposition |
| EP04785621A | Sep, 2017 | Generics [UK] Ltd | Revoked |
| EP08000358A | May, 2017 | Bülle Dr., Jan | Revoked |
| EP08000358A | May, 2017 | Teva Pharmaceutical Industries Ltd. | Revoked |
| EP08000358A | May, 2017 | CHEMO IBERICA, S.A. | Revoked |
| EP08000358A | Apr, 2017 | Pharmaceutical Works Polpharma | Revoked |
| EP11190103A | Mar, 2016 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Patent maintained as amended |
| EP04002427A | Jan, 2011 | Teva Pharmaceutical Industries Ltd. | Patent maintained as amended |
| EP02782507A | Jan, 2007 | Ratiopharm GmbH | Revoked |
| EP02782507A | Jan, 2007 | EGIS Gyógyszergyár Nyrt | Revoked |
| EP02782507A | Jan, 2007 | Pharmaceutical Works POLPHARMA | Revoked |
| EP02782507A | Jan, 2007 | Fermion Oy | Revoked |
| EP02782507A | Jan, 2007 | Teva Pharmaceutical Industries Ltd. | Revoked |
Otsuka's Family Patents
Otsuka drugs have patent protection in a total of 59 countries. It's US patent count contributes only to 25.2% of its total global patent coverage. 9 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Otsuka Drug List
Given below is the complete list of Otsuka's drugs and the patents protecting them.
1. Abilify
Abilify is protected by 25 patents, out of which 20 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
02 Mar, 2027
(2 years from now)
| Active |
| US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders |
28 Jul, 2026
(1 year, 8 months from now)
| Active |
| US7115587
(Pediatric)
| Aripiprazole complex formulation and method |
21 Jan, 2025
(2 months from now)
| Active |
| US7550445
(Pediatric)
| Aripiprazole complex formulation and method |
21 Jan, 2025
(2 months from now)
| Active |
| US8017615
(Pediatric)
| Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
16 Dec, 2024
(30 days from now)
| Active |
| US7115587 | Aripiprazole complex formulation and method |
21 Jul, 2024
(3 months ago)
| Expired |
| US7550445 | Aripiprazole complex formulation and method |
21 Jul, 2024
(3 months ago)
| Expired |
| US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
16 Jun, 2024
(4 months ago)
| Expired |
| US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
25 Dec, 2023
(10 months ago)
| Expired |
| US8580796
(Pediatric)
| Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US8642760
(Pediatric)
| Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Mar, 2023
(1 year, 7 months ago)
| Expired |
| US6977257
(Pediatric)
| Aripiprazole oral solution |
24 Oct, 2022
(2 years ago)
| Expired |
| US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US8642600
(Pediatric)
| Method of treating autism |
28 Jul, 2022
(2 years ago)
| Expired |
| US6977257 | Aripiprazole oral solution |
24 Apr, 2022
(2 years ago)
| Expired |
| US7053092 | 5-HT1a receptor subtype agonist |
28 Jan, 2022
(2 years ago)
| Expired |
| US8642600 | Method of treating autism |
28 Jan, 2022
(2 years ago)
| Expired |
| US9089567 | Method of treating cognitive impairments and schizophrenias |
28 Jan, 2022
(2 years ago)
| Expired |
| US8518421
(Pediatric)
| Flashmelt oral dosage formulation |
24 Jul, 2021
(3 years ago)
| Expired |
| US8518421 | Flashmelt oral dosage formulation |
24 Jan, 2021
(3 years ago)
| Expired |
| US9358207 | Flashmelt oral dosage formulation |
12 Apr, 2020
(4 years ago)
| Expired |
| US5006528
(Pediatric)
| Carbostyril derivatives |
20 Apr, 2015
(9 years ago)
| Expired |
| US5006528 | Carbostyril derivatives |
20 Oct, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abilify's drug page
2. Abilify Asimtufii
Abilify Asimtufii is protected by 8 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10517951 | Injectable preparation |
23 Apr, 2033
(8 years from now)
| Active |
| US11097007 | Injectable preparation |
23 Apr, 2033
(8 years from now)
| Active |
| US11638757 | Injectable preparation |
23 Apr, 2033
(8 years from now)
| Active |
| US12016927 | Injectable preparation |
23 Apr, 2033
(8 years from now)
| Active |
| US8399469 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
29 Jun, 2025
(7 months from now)
| Active |
| US8338427 | Methods for administering aripiprazole |
15 Mar, 2025
(3 months from now)
| Active |
| US8338428 | Methods for administering aripiprazole |
06 Aug, 2023
(1 year, 3 months ago)
| Expired |
| US8759351 | Methods for administering aripiprazole |
06 Aug, 2023
(1 year, 3 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abilify Asimtufii's drug page
3. Abilify Mycite Kit
Abilify Mycite Kit is protected by 38 patents, out of which 7 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10097388 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
19 Sep, 2034
(9 years from now)
| Active |
| US9270503 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
19 Sep, 2034
(9 years from now)
| Active |
| US9787511 | Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping |
19 Sep, 2034
(9 years from now)
| Active |
| US9268909 | Apparatus, system, and method to adaptively optimize power dissipation and broadcast power in a power source for a communication device |
15 Oct, 2033
(8 years from now)
| Active |
| US9577864 | Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance |
03 Oct, 2033
(8 years from now)
| Active |
| US10517507 | Communication system with enhanced partial power source and method of manufacturing same |
13 Jun, 2032
(7 years from now)
| Active |
| US9320455 | Highly reliable ingestible event markers and methods for using the same |
15 Dec, 2031
(7 years from now)
| Active |
| US11229378 | Communication system with enhanced partial power source and method of manufacturing same |
11 Jul, 2031
(6 years from now)
| Active |
| US8547248 | Implantable zero-wire communications system |
18 Dec, 2030
(6 years from now)
| Active |
| US8258962 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
25 Nov, 2030
(6 years from now)
| Active |
| US8961412 | In-body device with virtual dipole signal amplification |
17 Nov, 2030
(6 years from now)
| Active |
| US9941931 | System for supply chain management |
04 Nov, 2030
(5 years from now)
| Active |
| US11464423 | In-body power source having high surface area electrode |
15 Sep, 2030
(5 years from now)
| Active |
| US8114021 | Body-associated receiver and method |
21 Jun, 2030
(5 years from now)
| Active |
| US8545402 | Highly reliable ingestible event markers and methods for using the same |
27 Apr, 2030
(5 years from now)
| Active |
| US8847766 | Pharma-informatics system |
29 Mar, 2030
(5 years from now)
| Active |
| US9149577 | Body-associated receiver and method |
15 Dec, 2029
(5 years from now)
| Active |
| US8718193 | Active signal processing personal health signal receivers |
05 Dec, 2029
(5 years from now)
| Active |
| US9433371 | In-body device with virtual dipole signal amplification |
15 Sep, 2029
(4 years from now)
| Active |
| US8945005 | Controlled activation ingestible identifier |
19 Aug, 2029
(4 years from now)
| Active |
| US10441194 | Ingestible event marker systems |
26 Jul, 2029
(4 years from now)
| Active |
| US8956288 | In-body power source having high surface area electrode |
06 Jul, 2029
(4 years from now)
| Active |
| US8674825 | Pharma-informatics system |
09 Apr, 2029
(4 years from now)
| Active |
| US9060708 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
05 Mar, 2029
(4 years from now)
| Active |
| US9258035 | Multi-mode communication ingestible event markers and systems, and methods of using the same |
05 Mar, 2029
(4 years from now)
| Active |
| US9119554 | Pharma-informatics system |
16 Dec, 2028
(4 years from now)
| Active |
| US9444503 | Active signal processing personal health signal receivers |
19 Nov, 2027
(3 years from now)
| Active |
| US8759350 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
02 Mar, 2027
(2 years from now)
| Active |
| US7978064 | Communication system with partial power source |
14 Sep, 2026
(1 year, 9 months from now)
| Active |
| US9125939 | Carbostyril derivatives and mood stabilizers for treating mood disorders |
28 Jul, 2026
(1 year, 8 months from now)
| Active |
| US11476952 | Pharma-informatics system |
28 Apr, 2026
(1 year, 5 months from now)
| Active |
| US8017615 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
16 Jun, 2024
(4 months ago)
| Expired |
| US9387182 | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
25 Dec, 2023
(10 months ago)
| Expired |
| US8580796 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US8642760 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US9359302 | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
25 Sep, 2022
(2 years ago)
| Expired |
| US7053092 | 5-HT1a receptor subtype agonist |
28 Jan, 2022
(2 years ago)
| Expired |
| US9089567 | Method of treating cognitive impairments and schizophrenias |
28 Jan, 2022
(2 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Abilify Mycite Kit's drug page
4. Inqovi
Inqovi is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11963971 | Combination decitabine and cedazuridine solid oral dosage forms |
24 Feb, 2041
(16 years from now)
| Active |
| US8268800 | Certain compounds, compositions and methods |
22 Aug, 2030
(5 years from now)
| Active |
| US8618075 | Certain compounds, compositions and methods |
16 Oct, 2028
(3 years from now)
| Active |
| US9567363 | Certain compounds, compositions and methods |
16 Oct, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inqovi's drug page
5. Jynarque
Jynarque is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10905694 | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
07 Apr, 2030
(5 years from now)
| Active |
| US8501730 | Process for preparing benzazepine compounds or salts thereof |
01 Sep, 2026
(1 year, 9 months from now)
| Active |
| US5753677 | Benzoheterocyclic compounds |
19 May, 2020
(4 years ago)
| Expired |
| US5972882 | Treatment of polycystic kidney disease using vasopressin V2 receptor antagonists |
14 Dec, 2018
(5 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jynarque's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
6. Raxar
Raxar is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5563138 | Benzoheterocyclic compounds |
08 Oct, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Raxar's drug page
7. Rexulti
Rexulti is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10307419
(Pediatric)
| Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
12 Apr, 2033
(8 years from now)
| Active |
| US10307419 | Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof |
12 Oct, 2032
(7 years from now)
| Active |
| USRE48059
(Pediatric)
| Piperazine-substituted benzothiophenes for treatment of mental disorders |
23 Jun, 2029
(4 years from now)
| Active |
| USRE48059 | Piperazine-substituted benzothiophenes for treatment of mental disorders |
23 Dec, 2028
(4 years from now)
| Active |
| US7888362
(Pediatric)
| Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8349840
(Pediatric)
| Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Oct, 2026
(1 year, 10 months from now)
| Active |
| US8618109
(Pediatric)
| Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Oct, 2026
(1 year, 10 months from now)
| Active |
| US9839637
(Pediatric)
| Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Oct, 2026
(1 year, 10 months from now)
| Active |
| US7888362 | Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Apr, 2026
(1 year, 4 months from now)
| Active |
| US8349840 | Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Apr, 2026
(1 year, 4 months from now)
| Active |
| US8618109 | Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Apr, 2026
(1 year, 4 months from now)
| Active |
| US9839637 | Piperazine-substituted benzothiophenes for treatment of mental disorders |
12 Apr, 2026
(1 year, 4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rexulti's drug page
8. Samsca
Samsca is protected by 4 patents, out of which 2 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10905694 | Pharmaceutical solid preparation comprising benzazepines and production method thereof |
07 Apr, 2030
(5 years from now)
| Active |
| US8501730 | Process for preparing benzazepine compounds or salts thereof |
01 Sep, 2026
(1 year, 9 months from now)
| Active |
| US5753677 | Benzoheterocyclic compounds |
19 May, 2015
(9 years ago)
| Expired |
| US5258510 | Benzoheterocyclic compounds |
02 Nov, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Samsca's drug page